|
| Press Releases |
|
 |
|
| Friday, May 16, 2025 |
|
|
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro |
| Eisai Co., Ltd. announced today that it has received notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) that the "all-case surveillance" post-marketing observational study condition required at the time of approval of anticancer agent "Remitoro for Intravenous Drip Infusion 300microgram" (Denileukin Diftitox (Genetical Recombination)) for the indications of T-cell Lymphoma has been cleared. more info >> |
|
| Wednesday, April 30, 2025 |
|
|
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star |
| Eisai Co., Ltd. announced today that its Representative Corporate Officer and CEO Haruo Naito has been selected to receive the Order of the Rising Sun, Gold and Silver Star at the 2025 Spring Conferment of Decorations. more info >> |
|
| Friday, April 18, 2025 |
|
|
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union |
| Eisai Co., Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing Authorization (MA) in the European Union (EU). more info >> |
|
| Tuesday, April 1, 2025 |
|
|
Eisai to Divest Rights for Pariet in China to Peak Pharma |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest the rights for proton pump inhibitor Pariet (generic name: rabeprazole sodium) in China to Beijing Peak Biology Pharmaceuticals Co., Ltd., a CBC Group-controlled company. more info >> |
|
| Tuesday, March 25, 2025 |
|
|
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards |
| Eisai Co., Ltd. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of early Alzheimer's disease (early AD ) has received the Prime Minister's Award at the 12th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES). more info >> |
|
|
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace |
| Eisai Co., Ltd. announced today that it has been selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as a Nadeshiko Brand 2025 as a listed company excelling in the promotion of women in the workplace. more info >> |
|
| Monday, March 10, 2025 |
|
|
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time |
| Eisai Co., Ltd. announced today that it has been recognized as the 2025 KENKO Investment for Health by Japan's Ministry of Economy, Trade, and Industry (METI) and the Tokyo Stock Exchange, for the first time as a company strategically carrying out efforts with regard to its employees' health from a management perspective. more info >> |
|
| Wednesday, March 5, 2025 |
|
|
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan |
| Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan regarding the orally-administered antifungal agent NAILIN Capsules 100 mg (generic name: fosravuconazole) which is manufactured and marketed by Sato Pharmaceutical, as of March 31, 2025. more info >> |
|
| Tuesday, March 4, 2025 |
|
|
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial decision to decline the approval of humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody lecanemab (generic name) as a treatment for early Alzheimer's disease (AD) (mild cognitive impairment due to AD and mild AD dementia). more info >> |
|
| Monday, March 3, 2025 |
|
|
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell" |
| Eisai Co., Ltd. announced today the launch of the new nutritional drink "Chocola BB Nightwell" (designated quasi-drug product), a nutritional drink to help recovery from the accumulated fatigue of the day during sleep, on Monday, March 3. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Hitachi Launches Expanded HMAX Solutions Accelerating Social Innovation Globally Across Industries
Jan 7, 2026 12:27 JST
|
|
|
Fullerton Health Deepens Specialty Care Capabilities Through Acquisition of Singapore-Based Otolaryngology Practice, The ENT Clinic
Jan 7, 2026 10:30 HKT/SGT
|
|
|
Radisson Announces Additional High-Grade Drill Results and Further Extends New Mineralization Beneath the Historic O'Brien Gold Mine
Jan 6, 2026 20:00 HKT/SGT
|
|
|
Hong Kong Toys & Games Fair leads market innovation, debut 'Pop & Play' pavilion opens to industry and public
Jan 6, 2026 18:50 HKT/SGT
|
|
|
CTF Life Amplifies Ecosystem Synergy
Jan 6, 2026 15:35 HKT/SGT
|
|
|
Mitsubishi Motors to Celebrate "Delica Festival" with Custom Versions of Delica D:5 and Delica Mini at Tokyo Auto Salon 2026
Jan 6, 2026 16:25 JST
|
|
|
Mitsubishi Motors Launches the Xforce in Taiwan
Jan 6, 2026 14:42 JST
|
|
|
">
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
Jan 6, 2026 10:43 JST
|
|
|
Asian Financial Forum kicks off 2026 as region's first major event of 2026 
Jan 6, 2026 04:41 HKT/SGT
|
|
|
Notice on the Establishment of a Special Subsidiary
Jan 5, 2026 21:00 HKT/SGT
|
|
|
TANAKA Announces Executive Appointment
Jan 5, 2026 21:00 HKT/SGT
|
|
|
Asian Financial Forum kicks off 2026 as region's first major event of 2026
Jan 5, 2026 15:39 HKT/SGT
|
|
|
Alpha Growth plc: Alpha Longevity Management Ltd Expands Global Platform with Launch of Alpha Alternative Global Fund and Strengthening of Executive Leadership Team
Jan 5, 2026 16:00 JST
|
|
|
The Tampere city region chose Fujitsu to deliver and develop the area's ICT services
Jan 5, 2026 15:23 JST
|
|
|
AVIA's Coalition Against Piracy Secures New Singapore Court Order Blocking 53 Illegal Streaming Domains
Jan 5, 2026 13:35 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
